Role of a healthcare provider in adherence and outcomes of patients using gut-directed hypnotherapy digital therapeutic

‍Results ‍

There was a higher proportion of users who were not referred by a health care provider (n=21,136) compared to users referred by a health care provider (n=1,361). The proportion of users who completed the final session was significantly higher in the health care provider referred group compared to the not referred group (referred: n=505, 37%, not referred: n=5,159, 24.4%). The proportion of users who completed the symptom report prior to finishing the last session also was significantly higher in the referred group (referred: n=309, 22.7%, not referred: n=3,076, 14.5%). Finally, the proportion of users who saw overall GI symptom improvement based on the IBS-VAS was higher in the referred group compared to the not referred group (referred: n=241, 17.7%, not referred: n=2,521, 11.9%). 78% of the users referred by a health care provider who filled out the post-program questionnaire saw improvement. Users who were referred were 1.5x more likely to finish the program. 82% of the users not referred by a health care provider who filled out the post-program questionnaire saw improvement. However, these users were 1.5x less likely to finish the program compared to users who were referred by a health care provider. (Figure 1)

Discussion

‍This is a brief look into the role of a health care provider referral into patient success using a digital therapeutic. We found that patients who are referred are more likely to finish the program and see beneficial results. The findings suggest that patients who are referred by a health care provider are more accountable to the program and therefore see benefit in a greater proportion. Patients who are not referred are still seeing the same symptom improvement as those referred but are less likely to finish the program. There is more to understand regarding the role of the health care team in digital therapeutics, however, a simple referral can have lasting effects on the patient adherence and outcome.

Refer your patients to Nerva using our HIPAA-compliant form.

‍

1. Hillilä, M.T. and M.A. Färkkilä, Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population. Aliment Pharmacol Ther, 2004. 20(3): p. 339-45.

2. Canavan, C., J. West, and T. Card, The epidemiology of irritable bowel syndrome. Clinical epidemiology, 2014. 6: p. 71-80.

3. Canavan, C., J. West, and T. Card, The economic impact of the irritable bowel syndrome. Alimentary pharmacology & therapeutics, 2014. 40(9): p. 1023-1034.

‍